|

Cancer Clinical Trials in West Virginia

144 recruiting studies across 12 cities

All Trials in West Virginia

Phase
Trial Phase Location
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Bridgeport
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/ABridgeport
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPhase 2Bridgeport
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Bridgeport
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Bridgeport
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects—Bridgeport
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Bridgeport
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Bridgeport
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaPhase 3Bridgeport
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Bridgeport
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/ABridgeport
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck CancerPhase 3Bridgeport
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors—Bridgeport
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Bridgeport
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3Bridgeport
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Bridgeport
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Bridgeport
Reaching Rural Cancer Survivors Who Smoke Using Text-Based ProgramPhase 3Bridgeport
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Bridgeport
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Bridgeport
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Bridgeport
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Bridgeport
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPhase 3Bridgeport
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPhase 3Bridgeport
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Bridgeport
Galleri® in the Medicare Population.N/ABuckhannon
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 3Charleston
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerPhase 3Charleston
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPhase 3Charleston
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Charleston
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTPhase 2Charleston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Charleston
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Charleston
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPhase 3Charleston
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Phase 3Charleston
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Charleston
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 4Charleston
Blue Light Cystoscopy With Cysview® Registry—Charleston
Caris Biorepository Research Protocol—Charleston
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Charleston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPhase 3Charleston
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPhase 3Charleston
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)Phase 3Charleston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Charleston
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Charleston
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Charleston
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Charleston
Project: Every Child for Younger Patients With Cancer—Charleston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Charleston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Phase 3Charleston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2Charleston
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialPhase 2Charleston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 3Charleston
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPhase 3Charleston
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPhase 2/3Charleston
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialPhase 2Charleston
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Charleston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Charleston
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Charleston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2Huntington
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Huntington
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Huntington
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Huntington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Huntington
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Huntington
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Huntington
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderPhase 2Huntington
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialPhase 2Huntington
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3Huntington
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Huntington
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT—Huntington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Huntington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Huntington
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Huntington
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPhase 3Huntington
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Huntington
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur TrialPhase 2Huntington
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural PatientsN/ALewisburg
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Martinsburg
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Phase 3Morgantown
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Phase 3Morgantown
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Phase 3Morgantown
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic CancerPhase 1Morgantown
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—Morgantown
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerPhase 3Morgantown
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesPhase 2Morgantown
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3Morgantown
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1Morgantown
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 2Morgantown
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Phase 3Morgantown
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Phase 3Morgantown
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Morgantown
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerPhase 2Morgantown
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Phase 2Morgantown
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPhase 2Morgantown
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPhase 3Morgantown
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaPhase 3Morgantown
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumPhase 2Morgantown
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)Phase 3Morgantown
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsPhase 1Morgantown
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerPhase 2Morgantown
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix CancerN/AMorgantown
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPhase 1/2Morgantown
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.—Morgantown
Abatacept in Immune Checkpoint Inhibitor MyocarditisPhase 3Morgantown
Actinic Keratoses Treated With 5-fluorouracil Plus AluminumPhase 1Morgantown
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers—Morgantown
CREO - Microwave Ablation Feasibility StudyN/AMorgantown
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 3Morgantown
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLPhase 2Morgantown
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialPhase 2Morgantown
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinPhase 3Morgantown
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—Morgantown
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaPhase 2Morgantown
Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue ManagementN/AMorgantown
Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium ChloridePhase 1/2Morgantown
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 3Morgantown
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPhase 3Morgantown
Pioglitazone Therapy Targeting Fatigue in Breast CancerPhase 2Morgantown
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaPhase 2/3Morgantown
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaPhase 2Morgantown
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)Phase 3Morgantown
Rural Adult and Youth Sun Protection StudyN/AMorgantown
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Morgantown
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Phase 2/3Morgantown
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerPhase 3Morgantown
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)N/AMorgantown
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/AMorgantown
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3Morgantown
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPhase 3Morgantown
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Phase 3Morgantown
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Morgantown
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerPhase 3Morgantown
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 3Morgantown
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)Phase 2Morgantown
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyPhase 3Morgantown
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Morgantown
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialPhase 2Morgantown
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)Phase 2Morgantown
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPhase 1/2Morgantown
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Morgantown
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPhase 3Morgantown
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLPhase 3Wheeling
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3Wheeling

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.